By Soren Jeppesen and Jacob Gronholt-Pedersen

KALUNDBORG, Denmark (Reuters) -In Denmark’s seaside town of Kalundborg, also known as “Novo Town”, therapist Heidi Thron Rune has learnt to live with the noise of building work as new facilities take shape to meet demand for Novo Nordisk’s Wegovy weight-loss drug.

What is less familiar is the worry that has taken hold as the pharmaceutical company that has become central to the Danish economy readies to cut some 5,000 jobs in its home market.

“I think everyone is just holding their breath,” Kalundborg’s Deputy Mayor Tina Beck-Nilsson told Reuters at a cafe in the town centre overlooking the harbour front.

Wegovy, launched in 2021, made Novo Nordisk Europe’s most valuable company last year.

Since then, fierce competition in the United State

See Full Page